
By controlling for ovarian suppression, OPTIMA shows Prosigna works equally well in pre and postmenopausal high-risk early breast cancer.

By controlling for ovarian suppression, OPTIMA shows Prosigna works equally well in pre and postmenopausal high-risk early breast cancer.

OPTIMA trial data show genomic testing helps many patients with high‑risk breast cancer skip chemotherapy safely and start endocrine therapy sooner.

ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.